Associate Professor Jim Manos has established his research career in the field of bacterial pathogenesis. He completed his PhD studies at the University of New South Wales, Sydney Australia and subsequently carried out postdoctoral studies at the University of Maryland Medical School, Baltimore, USA, on Proteus mirabilis. Since 2004 at the University of Sydney he has worked on cystic fibrosis lung infections and biofilms.
As Head of the Bacterial Pathogens Research group, he has refined and validated an artificial sputum medium which mimics CF sputum and has used this to detect novel differentially expressed bacterial genes. Current focus of his group is the disruption of bacterial biofilms using antioxidants. The group has shown that antioxidants coupled with antibiotics significantly reduce biofilm size, mass and structure.
He has 34 publications in high quality peer-reviewed journals, four book chapters and three patents. He has been funded by the Australian CF Research Trust, National Health and Medical Research Council and University-based funding sources, a CDIP grant from the University of Sydney and an innovation (iMCRC) grant with an industry partner to expand and develop the group’s findings on biofilm disruption methods.
Associate Professor Jim Manos has established his research career in the field of bacterial pathogenesis. He completed his PhD studies at the University of New South Wales, Sydney Australia and subsequently carried out postdoctoral studies at the University of Maryland Medical School, Baltimore, USA, on Proteus mirabilis. Since 2004 at the University of Sydney he has worked on cystic fibrosis lung infections and biofilms.
As Head of the Bacterial Pathogens Research group, he has refined and validated an artificial sputum medium which mimics CF sputum and has used this to detect novel differentially expressed bacterial genes. Current focus of his group is the disruption of bacterial biofilms using antioxidants. The group has shown that antioxidants coupled with antibiotics significantly reduce biofilm size, mass and structure.
He has 34 publications in high quality peer-reviewed journals, four book chapters and three patents. He has been funded by the Australian CF Research Trust, National Health and Medical Research Council and University-based funding sources, a CDIP grant from the University of Sydney and an innovation (iMCRC) grant with an industry partner to expand and develop the group’s findings on biofilm disruption methods.